Eli Lilly And Company

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

Lilly confirms date and conference call for first-quarter 2026 financial results announcement

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide

Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform